Related Experiment Videos

Thrombolytic eligibility

C J Ellis1, J K French, H D White

  • 1Department of Medicine, Auckland Hospital, New Zealand.

Australian and New Zealand Journal of Medicine
|October 20, 1998
PubMed

Insights

Thrombolytic therapy benefits patients with ischemic chest pain and ST elevation or bundle branch block on ECG. This treatment is recommended for specific patient subsets, including those with inferior myocardial infarction and delayed presentation.

Area of Science:

  • Cardiology
  • Emergency Medicine
  • Pharmacology

Background:

  • Ischemic chest pain requires prompt diagnosis and treatment.
  • Electrocardiogram (ECG) findings guide the decision for thrombolytic therapy.
  • The Fibrinolytic Therapy Trialists' Collaborative Group established benefits for specific patient groups.

Purpose of the Study:

  • To evaluate thrombolytic eligibility in various patient subsets presenting with ischemic chest pain.
  • To explore benefits in patients with inferior myocardial infarction.
  • To confirm treatment benefits for patients presenting 6-12 hours after symptom onset.

Main Methods:

  • Analysis of data from the Fibrinolytic Therapy Trialists' Collaborative Group.
  • Review of ECG criteria for thrombolytic therapy eligibility.
  • Examination of treatment outcomes in specific patient subgroups.

Main Results:

  • Patients with ischemic chest pain, ST elevation or bundle branch block on ECG benefit from thrombolytic therapy.
  • Therapy is beneficial for patients with inferior myocardial infarction.
  • Patients presenting 6-12 hours after symptom onset also show treatment benefits.

Conclusions:

  • Thrombolytic therapy should be considered for eligible patients regardless of specific conditions.
  • Diabetic patients, elderly patients, menstruating women, and those who have undergone cardiopulmonary resuscitation should not be routinely excluded.
  • ECG interpretation remains crucial for guiding thrombolytic treatment decisions.

Related Concept Videos